| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Address correspondence and reprint requests to Dr. Mark S. Freedman, The Ottawa Hospital–General Campus, 501 Smyth Road, Ottawa, Ontario, Canada K1H 8L6; e-mail: mfreedman{at}ogh.on.ca
OBJECTIVE: To compare efficacy of interferon ß-1a, 22 µg or 44 µg weekly, with placebo in relapsing MS.
BACKGROUND: Uncertainty exists concerning the optimal dose regimen for interferon ß in relapsing-remitting MS. Many patients and physicians prefer the convenience and lesser side effects of an injection given once weekly (qw) as opposed to three times weekly. Pharmacokinetic data and information on biologic markers suggest that this frequency may be suboptimal.
METHODS: Randomized, double-blind study of interferon ß-1a 22 µg, 44 µg, or placebo administered by weekly subcutaneous injection for 48 weeks. Proton density (PD)/T2-weighted and T1-weighted–gadolinium MRI scans during 24 weeks of therapy were analyzed for the number of combined unique (CU) lesions (primary outcome). Biannual PD/T2 scans were analyzed for T2 activity and burden of disease (BOD).
RESULTS: CU lesions at 24 weeks had a median of 0.71/scan with placebo, 0.5/scan with 22 µg (not significant), and 0.33/scan with 44 µg (p = 0.002). T2 new lesion count/scan (mean/median) at 48 weeks was 3.2/1.5 for placebo, 2.4/1.0 for 22 µg (p = 0.03), and 1.5/1.0 for 44 µg (p = 0.0005). BOD at 48 weeks showed a median increase of 5.9% for placebo compared with a decrease of 1.4% in the 44 µg group (p = 0.0058) and 2% in the 22 µg group (p = 0.0018). No clinical variable, apart from steroid use in the 44 µg qw group (p = 0.014), showed significance.
CONCLUSIONS: These data confirm an MRI benefit of interferon ß-1a at low dose in MS, but highlight the limited clinical effect. Taken together with other studies, the data demonstrate a dose–effect relationship for both clinical and MRI variables.
Key words: Multiple sclerosis—Interferon-ß—Dose–response relationship.
This article has been cited by other articles:
|
|
 |
|
  B. S. Oken Placebo effects: clinical aspects and neurobiology Brain, June 21, 2008; (2008) awn116v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Farrell, R. Kapoor, S. Leary, P. Rudge, A. Thompson, D. Miller, and G. Giovannoni Neutralizing anti-interferon beta antibodies are associated with reduced side effects and delayed impact on efficacy of Interferon-beta Multiple Sclerosis, March 1, 2008; 14(2): 212 - 218. [Abstract] [PDF]
|
|
|
|
 |
|
 M. G. Brown, S. Kirby, C. Skedgel, J. D. Fisk, T. J. Murray, V. Bhan, and I. S. Sketris How effective are disease-modifying drugs in delaying progression in relapsing-onset MS? Neurology, October 9, 2007; 69(15): 1498 - 1507. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. A Farrell and G. Giovannoni Measuring and management of Anti-Interferon Beta Antibodies in subjects with Multiple Sclerosis Multiple Sclerosis, June 1, 2007; 13(5): 567 - 577. [Abstract] [PDF]
|
|
|
|
|
|
A. AL-Sabbagh Neutralizing antibodies in MS therapy: reviewing the Rebif experience Multiple Sclerosis, May 1, 2007; 13(1_suppl): 8 - 13. [Abstract] [PDF]
|
|
|
|
|
|
C Gneiss, P Tripp, F Reichartseder, R Egg, R Ehling, A Lutterotti, M Khalil, B Kuenz, I Mayringer, M Reindl, et al. Differing immunogenic potentials of interferon beta preparations in multiple sclerosis patients Multiple Sclerosis, November 1, 2006; 12(6): 731 - 737. [Abstract] [PDF]
|
|
|
|
|
|
D. S. Goodin, N. Koch-Henriksen, and P. S. Sorensen A randomized study of two interferon-beta treatments in relapsing-remitting multiple sclerosis. Neurology, October 10, 2006; 67(7): 1313 - 1314. [Full Text] [PDF]
|
|
|
|
|
|
L. Kappos, C. H. Polman, M. S. Freedman, G. Edan, H. P. Hartung, D. H. Miller, X. Montalban, F. Barkhof, L. Bauer, P. Jakobs, et al. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes Neurology, October 10, 2006; 67(7): 1242 - 1249. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Tremlett and V. Devonshire Is late-onset multiple sclerosis associated with a worse outcome? Neurology, September 26, 2006; 67(6): 954 - 959. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L L. Mantia, D D'Amico, A Rigamonti, N Mascoli, G Bussone, and C Milanese Interferon treatment may trigger primary headaches in multiple sclerosis patients Multiple Sclerosis, August 1, 2006; 12(4): 476 - 480. [Abstract] [PDF]
|
|
|
|
|
|
W. Pollmann, L.-P. Erasmus, W. Feneberg, and A. Straube The effect of glatiramer acetate treatment on pre-existing headaches in patients with MS Neurology, January 24, 2006; 66(2): 275 - 277. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Sandberg-Wollheim, D. Frank, T. M. Goodwin, B. Giesser, M. Lopez-Bresnahan, M. Stam-Moraga, P. Chang, and G. S. Francis Pregnancy outcomes during treatment with interferon beta-1a in patients with multiple sclerosis Neurology, September 27, 2005; 65(6): 802 - 806. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. S. Francis, G. P.A. Rice, J. C. Alsop, and for the PRISMS (Prevention of Relapses and Disabil Interferon {beta}-1a in MS: Results following development of neutralizing antibodies in PRISMS Neurology, July 12, 2005; 65(1): 48 - 55. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. B Patten, G. Francis, L. M Metz, M. Lopez-Bresnahan, P. Chang, and F. Curtin The relationship between depression and interferon beta-1a therapy in patients with multiple sclerosis Multiple Sclerosis, April 1, 2005; 11(2): 175 - 181. [Abstract] [PDF]
|
|
|
|
|
|
M S Freedman, G S Francis, E A. Sanders, G P. Rice, P O'Connor, G Comi, P Duquette, L Metz, T J Murray, J-P Bouchard, et al. Randomized study of once-weekly interferon {beta}-1a therapy in relapsing multiple sclerosis: three-year data from the OWIMS study Multiple Sclerosis, February 1, 2005; 11(1): 41 - 45. [Abstract] [PDF]
|
|
|
|
|
|
T. K. Vartanian, S. S. Zamvil, E. Fox, and P. S. Sorensen Neutralizing antibodies to disease-modifying agents in the treatment of multiple sclerosis Neurology, December 14, 2004; 63(11_suppl_5): S42 - S49. [Abstract] [Full Text]
|
|
|
|
 |
|
 O Andersen, I Elovaara, M Farkkila, H J Hansen, S I Mellgren, K-M Myhr, M Sandberg-Wollheim, and P Soelberg Sorensen Multicentre, randomised, double blind, placebo controlled, phase III study of weekly, low dose, subcutaneous interferon beta-1a in secondary progressive multiple sclerosis J. Neurol. Neurosurg. Psychiatry, May 1, 2004; 75(5): 706 - 710. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Rudge Interferon antibodies: do they alter the beneficial effects of beta-interferon upon relapse rate in multiple sclerosis? Multiple Sclerosis, April 1, 2004; 10(2): 123 - 125. [PDF]
|
|
|
|
|
|
M Clanet, L Kappos, H-P Hartung, R Hohlfeld, and The European IFNss-1a Dose-Comparison Study Invest Interferon {beta}-1a in relapsing multiple sclerosis: four-year extension of the European IFN{beta}-1a Dose-C omparison Study Multiple Sclerosis, April 1, 2004; 10(2): 139 - 144. [Abstract] [PDF]
|
|
|
|
|
|
J. A. Frank, N. Richert, C. Bash, L. Stone, P. A. Calabresi, B. Lewis, R. Stone, T. Howard, and H. F. McFarland Interferon-{beta}-1b slows progression of atrophy in RRMS: Three-year follow-up in NAb- and NAb+ patients Neurology, March 9, 2004; 62(5): 719 - 725. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S Nikolaus, P Rutgeerts, R Fedorak, A H Steinhart, G E Wild, D Theuer, J Mohrle, and S Schreiber Interferon {beta}-1a in ulcerative colitis: a placebo controlled, randomised, dose escalating study Gut, September 1, 2003; 52(9): 1286 - 1290. [Abstract] [Full Text]
|
|
|
|
 |
|
 C. L M Sudlow and C. E Counsell Problems with UK government's risk sharing scheme for assessing drugs for multiple sclerosis BMJ, February 15, 2003; 326(7385): 388 - 392. [Full Text] [PDF]
|
|
|
|
|
|
H. Panitch, D.S. Goodin, G. Francis, P. Chang, P.K. Coyle, P. O'Connor, E. Monaghan, D. Li, and B. Weinshenker Randomized, comparative study of interferon {beta}-1a treatment regimens in MS: The EVIDENCE Trial Neurology, November 26, 2002; 59(10): 1496 - 1506. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Clanet, E.W. Radue, L. Kappos, H.P. Hartung, R. Hohlfeld, M. Sandberg-Wollheim, M.F. Kooijmans-Coutinho, E.C. Tsao, and A.W. Sandrock A randomized, double-blind, dose-comparison study of weekly interferon {beta}-1a in relapsing MS Neurology, November 26, 2002; 59(10): 1507 - 1517. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G Giovannoni, F E Munschauer 3rd, and F Deisenhammer Neutralising antibodies to interferon beta during the treatment of multiple sclerosis J. Neurol. Neurosurg. Psychiatry, November 1, 2002; 73(5): 465 - 469. [Full Text] [PDF]
|
|
|
|
|
|
P. Coyle and H-P. Hartung Use of interferon beta in multiple sclerosis: rationale for early treatment and evidence for dose- and frequency-dependent effects on clinical response Multiple Sclerosis, September 1, 2002; 8(1_suppl): 2 - 9. [Abstract] [PDF]
|
|
|
|
|
|
M. Freedman, L. Blumhardt, B. Brochet, G. Comi, J. Noseworthy, M. Sandberg-Wollheim, and P. Soelberg Sorensen International consensus statement on the use of disease-modifying agents in multiple sclerosis Multiple Sclerosis, September 1, 2002; 8(1_suppl): 19 - 23. [Abstract] [PDF]
|
|
|
|
|
|
W. Pollmann, L. -P. Erasmus, W. Feneberg, F. T. Bergh, and A. Straube Interferon beta but not glatiramer acetate therapy aggravates headaches in MS Neurology, August 27, 2002; 59(4): 636 - 639. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A Bertolotto, S Malucchi, A Sala, G Orefice, P B Carrieri, M Capobianco, E Milano, F Melis, and M T Giordana Differential effects of three interferon betas on neutralising antibodies in patients with multiple sclerosis: a follow up study in an independent laboratory J. Neurol. Neurosurg. Psychiatry, August 1, 2002; 73(2): 148 - 153. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Bashir and J. N. Whitaker Current Immunotherapy for Demyelinating Diseases Arch Neurol, May 1, 2002; 59(5): 726 - 731. [Full Text] [PDF]
|
|
|
|
|
|
S. Dhib-Jalbut Mechanisms of action of interferons and glatiramer acetate in multiple sclerosis Neurology, April 23, 2002; 58(90084): S3 - 9. [Abstract] [Full Text]
|
|
|
|
|
|
P. A. Calabresi Considerations in the treatment of relapsing-remitting multiple sclerosis Neurology, April 23, 2002; 58(90084): S10 - 22. [Abstract] [Full Text]
|
|
|
|
|
|
M. Pia Sormani, P. Bruzzi, G. Comi, and M. Filippi MRI metrics as surrogate markers for clinical relapse rate in relapsing-remitting MS patients Neurology, February 12, 2002; 58(3): 417 - 421. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P K Coyle and H-P Hartung Use of interferon beta in multiple sclerosis: rationale for early treatment and evidence for dose- and frequency-dependent effects on clinical response Multiple Sclerosis, February 1, 2002; 8(1): 2 - 9. [Abstract] [PDF]
|
|
|
|
|
|
M S Freedman, L D Blumhardt, B Brochet, G Comi, J H Noseworthy, M Sandberg-Wollheim, P S. Sorensen, and Paris Workshop Group International consensus statement on the use of disease-modifying agents in multiple sclerosis Multiple Sclerosis, February 1, 2002; 8(1): 19 - 23. [Abstract] [PDF]
|
|
|
|
|
|
J D Lunemann, N Kassim, R Zschenderlein, F Zipp, and B Schwarzenberger Rhabdomyolysis during interferon-{beta} 1a treatment J. Neurol. Neurosurg. Psychiatry, February 1, 2002; 72(2): 274 - 274. [Full Text] [PDF]
|
|
|
|
|
|
D. S. Goodin, E. M. Frohman, G. P. Garmany Jr., J. Halper, W. H. Likosky, F. D. Lublin, D. H. Silberberg, W. H. Stuart, and S. van den Noort Disease modifying therapies in multiple sclerosis: Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines Neurology, January 22, 2002; 58(2): 169 - 178. [Full Text] [PDF]
|
|
|
|
|
|
PRISMS-4: Long-term efficacy of interferon-{beta}-1a in relapsing MS Neurology, June 26, 2001; 56(12): 1628 - 1636. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Randomized controlled trial of interferon- beta-1a in secondary progressive MS: Clinical results Neurology, June 12, 2001; 56(11): 1496 - 1504. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
European Study Group on Interferon-Beta-1a in MS Double-blind randomized multicenter dose-comparison study of interferon-{beta}-1a (AVONEX): rationale, design and baseline data Multiple Sclerosis, June 1, 2001; 7(3): 179 - 183. [Abstract] [PDF]
|
|
|
|
|
|
M P Sormani, D H Miller, G Comi, F Barkhof, M Rovaris, P Bruzzi, and M Filippi Clinical trials of multiple sclerosis monitored with enhanced MRI: new sample size calculations based on large data sets J. Neurol. Neurosurg. Psychiatry, April 1, 2001; 70(4): 494 - 499. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. H. Noseworthy, C. Lucchinetti, M. Rodriguez, and B. G. Weinshenker Multiple Sclerosis N. Engl. J. Med., September 28, 2000; 343(13): 938 - 952. [Full Text] [PDF]
|
|
|
|
|
|
C H Polman and B M J Uitdehaag Regular review: Drug treatment of multiple sclerosis BMJ, August 19, 2000; 321(7259): 490 - 494. [Full Text]
|
|
|
|
|
|
F. Deisenhammer, I. Mayringer, J. Harvey, E. Dilitz, T. Gasse, D. Stadlbauer, M. Reindl, and T. Berger A comparative study of the relative bioavailability of different interferon beta preparations Neurology, June 13, 2000; 54(11): 2055 - 2060. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
